Roche Holding AG
DUS:RHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Roche Holding AG
DUS:RHO
|
CH |
|
Braskem SA
BOVESPA:BRKM5
|
BR |
|
C
|
Corning Inc
XMUN:GLW
|
US |
|
B
|
Brown & Brown Inc
XMUN:BTW
|
US |
|
B
|
Boe Varitronix Ltd
XMUN:VTX
|
HK |
|
C
|
Corbion NV
XMUN:CSUA
|
NL |
|
N
|
Novo Nordisk A/S
XMUN:NOVA
|
DK |
|
Growthpoint Properties Ltd
F:G5JA
|
ZA |
|
En+ Group MKPAO
MOEX:ENPG
|
RU |
|
I
|
Ipsen SA
OTC:IPSEF
|
FR |
|
Lagardere SA
F:LAG
|
FR |
|
L
|
Leonardo SpA
XHAM:FMNB
|
IT |
|
Guerbet SA
PAR:GBT
|
FR |
|
P
|
Pacific Metals Co Ltd
F:PYV
|
JP |
|
Alsea SAB de CV
OTC:ALSSF
|
MX |
|
S
|
Showcase Minerals Inc
CNSX:SHOW
|
CA |
|
Decidr AI Industries Ltd
ASX:DAI
|
AU |
|
IDP Education Ltd
F:03F
|
AU |
Intrinsic Value
Is RHO undervalued or overvalued?
See the intrinsic value estimate for 
Roche Holding AG and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
RHO looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with RHO’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Roche Does
Roche Holding AG is a Swiss healthcare company that makes prescription medicines and diagnostic tests. Its drug business focuses on treatments in cancer, immunology, ophthalmology, and other serious diseases, while its diagnostics business sells instruments, lab tests, and software that help hospitals and laboratories detect disease and monitor patients. In simple terms, Roche helps doctors find illnesses and choose treatments, and it earns money by selling these medicines, test kits, and related systems to healthcare providers and distributors.
- Headquarters
- Switzerland CH
- Employees
- 100 920
- IPO date
- May 4, 2001
Roche Holding has no economic moat
Roche’s patents protect individual medicines for a time, but lower-priced copies and rival treatments can compete for customers when those protections end or another option is preferred. Patients and prescribers are not tied to Roche’s wider portfolio, and use of its medicines does not make them more valuable simply because more people use them; competitors can challenge Roche product by product.
Read the full moat analysis
Earnings Waterfall
Roche Holding AG
The intrinsic value for Roche Holding AG (RHO) under the Base Case is hidden EUR.
Compared with the current market price of 430.8 EUR, the stock appears hidden.